GB9718609D0 - Fusion protein - Google Patents

Fusion protein

Info

Publication number
GB9718609D0
GB9718609D0 GBGB9718609.2A GB9718609A GB9718609D0 GB 9718609 D0 GB9718609 D0 GB 9718609D0 GB 9718609 A GB9718609 A GB 9718609A GB 9718609 D0 GB9718609 D0 GB 9718609D0
Authority
GB
United Kingdom
Prior art keywords
fusion protein
fusion
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9718609.2A
Other languages
English (en)
Inventor
Andrea Crisanti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial College of London
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Imperial College of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd, Imperial College of London filed Critical Imperial College Innovations Ltd
Priority to GBGB9718609.2A priority Critical patent/GB9718609D0/en
Publication of GB9718609D0 publication Critical patent/GB9718609D0/en
Priority to JP2000508817A priority patent/JP2001514858A/ja
Priority to CA002301157A priority patent/CA2301157A1/en
Priority to AU88776/98A priority patent/AU737829B2/en
Priority to IL13460298A priority patent/IL134602A0/xx
Priority to BR9811744-0A priority patent/BR9811744A/pt
Priority to EP98940453A priority patent/EP1009847A1/en
Priority to NZ503007A priority patent/NZ503007A/xx
Priority to PCT/GB1998/002628 priority patent/WO1999011809A1/en
Priority to IL134602A priority patent/IL134602A/en
Priority to US10/789,403 priority patent/US7968512B2/en
Priority to US13/168,167 priority patent/US8735340B2/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Insects & Arthropods (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Variable-Direction Aerials And Aerial Arrays (AREA)
GBGB9718609.2A 1997-09-02 1997-09-02 Fusion protein Pending GB9718609D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB9718609.2A GB9718609D0 (en) 1997-09-02 1997-09-02 Fusion protein
PCT/GB1998/002628 WO1999011809A1 (en) 1997-09-02 1998-09-02 Conjugates that contain the homeodomain of antennapedia
IL13460298A IL134602A0 (en) 1997-09-02 1998-09-02 Conjugates that contain the homeodomain of antennapedia
CA002301157A CA2301157A1 (en) 1997-09-02 1998-09-02 Conjugates that contain the homeodomain of antennapedia
AU88776/98A AU737829B2 (en) 1997-09-02 1998-09-02 Conjugates that contain the homeodomain of antennapedia
JP2000508817A JP2001514858A (ja) 1997-09-02 1998-09-02 アンテナペディアのホメオドメインを含むコンジュゲート
BR9811744-0A BR9811744A (pt) 1997-09-02 1998-09-02 Conjugados contendo o homeodomìnio de antenapédia
EP98940453A EP1009847A1 (en) 1997-09-02 1998-09-02 Conjugates that contain the homeodomain of antennapedia
NZ503007A NZ503007A (en) 1997-09-02 1998-09-02 Conjugates that contain the homeodomain of antennapedia
IL134602A IL134602A (en) 1997-09-02 2000-02-17 Conjugates that contain the homeodomain of antennapedia
US10/789,403 US7968512B2 (en) 1997-09-02 2004-02-27 Conjugates that contain the homeodomain of antennapedia
US13/168,167 US8735340B2 (en) 1997-09-02 2011-06-24 Conjugates that contain the homeodomain of antennapedia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9718609.2A GB9718609D0 (en) 1997-09-02 1997-09-02 Fusion protein

Publications (1)

Publication Number Publication Date
GB9718609D0 true GB9718609D0 (en) 1997-11-05

Family

ID=10818419

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9718609.2A Pending GB9718609D0 (en) 1997-09-02 1997-09-02 Fusion protein

Country Status (10)

Country Link
US (2) US7968512B2 (enExample)
EP (1) EP1009847A1 (enExample)
JP (1) JP2001514858A (enExample)
AU (1) AU737829B2 (enExample)
BR (1) BR9811744A (enExample)
CA (1) CA2301157A1 (enExample)
GB (1) GB9718609D0 (enExample)
IL (2) IL134602A0 (enExample)
NZ (1) NZ503007A (enExample)
WO (1) WO1999011809A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130160A0 (en) * 1996-12-02 2000-06-01 Univ Wake Forest Inactivation of HIV co-receptors as therapy for HIV infection
US6221355B1 (en) * 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
JP4854853B2 (ja) 1998-11-12 2012-01-18 ライフ テクノロジーズ コーポレーション トランスフェクション薬剤
JP2002530059A (ja) * 1998-11-13 2002-09-17 サイクラセル・リミテッド 輸送ベクター
WO2000038733A1 (en) * 1998-12-24 2000-07-06 Ucb S.A. Peptidic product, process and composition
US6773920B1 (en) 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
AU775001B2 (en) * 1999-03-31 2004-07-15 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
IL150510A0 (en) * 2000-01-07 2003-02-12 Artemis Pharmaceuticals Gmbh Transduction of recombinases for inducible gene targeting
EP1118668A1 (en) * 2000-01-07 2001-07-25 ARTEMIS Pharmaceuticals GmbH Transduction of recombinases for inducible gene targeting
GB0003284D0 (en) * 2000-02-15 2000-04-05 Secr Defence Brit Anti-viral therapy
RU2002130200A (ru) * 2000-04-12 2004-03-27 Импликс Лтд. (Gb) Композиции для доставки лекарственного средства
DE10027777A1 (de) * 2000-06-07 2001-12-13 Otogene Ag Transfektionsverfahren
GB0015090D0 (en) * 2000-06-20 2000-08-09 Implyx Ltd Gene-activating conjugates
KR100374050B1 (ko) * 2000-07-26 2003-03-03 최수영 세포침투성 융합단백질, 이를 코딩하는 재조합폴리뉴클레오타이드 및 발현벡터
AU2001288955A1 (en) * 2000-09-07 2002-03-22 Vanderbilt University Genome engineering by cell-permeable dna site-specific recombinases
US6472176B2 (en) * 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
CA2367636C (en) 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
CA2452865A1 (en) * 2001-06-07 2002-12-12 Skinmedica, Inc. Conditioned cell culture media and uses thereof
US20050136040A1 (en) * 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
GB0124391D0 (en) * 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
DE102007041655A1 (de) 2007-09-03 2009-03-05 Medicyte Gmbh Vermehrung von primären Zellen und deren Verwendung
US8119366B2 (en) * 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
CA2758378A1 (en) 2009-04-14 2010-10-21 Trojan Technologies Ltd. Therapeutic antennapedia-antibody molecules and methods of use thereof
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
DE102010041958A1 (de) 2010-10-04 2012-04-05 Medicyte Gmbh Geeignete Hepatozyten für in-vitro Genotoxitätstests
WO2012154684A2 (en) * 2011-05-06 2012-11-15 University Of Rochester Method of preventing development of psoriatic lesions
ES2633343T3 (es) 2011-06-13 2017-09-20 The Board Of Trustees Of The University Of Illionis Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal
AU2013246034B2 (en) 2012-04-09 2017-12-07 Case Western Reserve University Compositions and methods for inhibiting the activity of LAR family phosphatases
US9884076B2 (en) 2012-06-05 2018-02-06 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP2882445B1 (en) 2012-08-13 2019-04-24 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
DK3581207T5 (da) 2013-06-11 2024-09-02 Ppl Bvi Ltd Fusionsproteiner omfattende hoxd12 og nemo-bindingsdomæne og anvendelse deraf
EP2927685A1 (en) 2014-04-02 2015-10-07 Medicyte GmbH Suitable hepatocytes for in-vitro hepatitis tests
CN106572974B (zh) 2014-07-15 2021-04-23 生命技术公司 用于将分子有效递送到细胞的具有脂质聚集体的组合物和方法
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
MX2017011170A (es) 2015-03-02 2018-04-24 Univ Illinois Peptidos para inhibir la angiogenesis.
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
WO2017177178A1 (en) 2016-04-07 2017-10-12 Case Western Reserve University Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
US11759482B2 (en) 2017-04-19 2023-09-19 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
CN111093684A (zh) 2017-07-11 2020-05-01 凯斯西储大学 用于治疗髓鞘病症的组合物和方法
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives

Also Published As

Publication number Publication date
US8735340B2 (en) 2014-05-27
IL134602A0 (en) 2001-04-30
US20080317773A1 (en) 2008-12-25
NZ503007A (en) 2000-11-24
BR9811744A (pt) 2002-01-02
US20110256168A1 (en) 2011-10-20
CA2301157A1 (en) 1999-03-11
AU8877698A (en) 1999-03-22
WO1999011809A1 (en) 1999-03-11
EP1009847A1 (en) 2000-06-21
JP2001514858A (ja) 2001-09-18
AU737829B2 (en) 2001-08-30
IL134602A (en) 2006-10-31
US7968512B2 (en) 2011-06-28

Similar Documents

Publication Publication Date Title
GB9718609D0 (en) Fusion protein
HUP0200414A2 (en) Interferon-betha fusion proteins and uses
PT1090128E (pt) Polipéptidos dependentes da vitamina k modificados
AU9482098A (en) Fusion protein systems
AU3562299A (en) Inhibin-hbc fusion protein
EP1088888A4 (en) MERGED PROTEIN
ZA976666B (en) Fusion polypeptides
ZA9710338B (en) Proteins
IL122898A0 (en) Allergan -XCD32 fusion proteins
GB9913437D0 (en) Fusion proteins
GB9719879D0 (en) Protein
GB9703681D0 (en) Protein complemention
AU9798398A (en) Gfp-annexin fusion proteins
GB9715064D0 (en) Protein expression
GB9701710D0 (en) Mammalian protein
ZA984322B (en) Sucrose-binding proteins
AU6000698A (en) Proteins
GB9720784D0 (en) Protein
GB9713150D0 (en) Fusion proteins
GB9604865D0 (en) Modified proteins
GB9813653D0 (en) Fusion proteins
GB9803757D0 (en) Fusion proteins
GB9720785D0 (en) Protein
GB9703103D0 (en) Protein
GB9719670D0 (en) Protein